The company will use the funds to scale-up production operations, expand commercial activities related to the AtomoRapid™ rapid diagnostic test (RDT) platform, as well as to commercialize a self-test solution for HIV and other infectious diseases.
As part of this collaborative funding agreement, GHIF and Atomo have made global access commitments to support and facilitate the launch and commercialization of Atomo’s professional use and self-test products in low and middle-income countries to ensure that they achieve the greatest possible global impact.
Led by John Kelly, chief executive officer, Atomo has developed a platform (The AtomoRapid™) that supports a wide range of clinical applications. The company is currently commercializing solutions for detection of HIV, malaria and Ebola, is finalizing development of an AtomoRapid™ Hepatitis C test and refining a combination test platform that can diagnose multiple diseases at once, as well as solutions with digital readers and e-health capabilities.
Structured by JPMorgan Chase & Co. and the Bill & Melinda Gates Foundation, with founding support from Grand Challenges Canada, KfW and SIDA, GHIF focuses on supporting companies addressing key global health challenges. It is led by Curt LaBelle, MD, president.